Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature

OBJECTIVES: Prostate cancer (PC) is the most common cancer in Western countries. Recent advances in the treatment of metastatic castration resistant prostate cancer (mCRPC) have caused significant pressure on health care budgets. We aimed to exemplify this dilemma presenting an example, radium-223 (...

Descripción completa

Detalles Bibliográficos
Autores principales: Norum, Jan, Traasdahl, Erik R., Totth, Arpad, Nieder, Carsten, Olsen, Jan Abel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Canadian Center of Science and Education 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873580/
https://www.ncbi.nlm.nih.gov/pubmed/26573043
http://dx.doi.org/10.5539/gjhs.v8n4p1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873580/
https://www.ncbi.nlm.nih.gov/pubmed/26573043
http://dx.doi.org/10.5539/gjhs.v8n4p1

Ejemplares similares